Zogenix Seeks Marketing Approval of Fintepla for Seizures in Japan

Zogenix Seeks Marketing Approval of Fintepla for Seizures in Japan

315949

Zogenix Seeks Marketing Approval of Fintepla for Seizures in Japan

Zogenix is seeking approval to market Fintepla (fenfluramine) in Japan as a treatment for epileptic seizures associated with Dravet syndrome. The company’s new drug application will be reviewed and decided on by the Japanese Ministry of Health, Labour, and Welfare. “There remains a substantial unmet need in the Dravet syndrome treatment landscape globally, and Japan is no exception where patients continue to experience refractory seizures that negatively impact quality of life,” Stephen J. Farr, PhD,…

You must be logged in to read/download the full post.